Patents by Inventor Nicolas Grandchamp

Nicolas Grandchamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR GENE EDITING
    Publication number: 20240060085
    Abstract: A method of therapeutic treatment by genome engineering in a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5? to 3? an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: m? indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one genome editor.
    Type: Application
    Filed: August 9, 2022
    Publication date: February 22, 2024
    Applicant: GEG TECH
    Inventor: Nicolas GRANDCHAMP
  • TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR COSMETIC USES
    Publication number: 20240060067
    Abstract: A method of treating skin and/or skin appendages in a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5? to 3?: an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest.
    Type: Application
    Filed: August 9, 2022
    Publication date: February 22, 2024
    Applicant: GEG TECH
    Inventor: Nicolas GRANDCHAMP
  • TRANSIENT EXPRESSION SYSTEM FOR RNA
    Publication number: 20240060084
    Abstract: A ribonucleic acid (RNA) that includes from 5? to 3?: an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); n” indicates any nucleotide; and a sequence of interest. Also, methods for robust transient RNA expression.
    Type: Application
    Filed: August 9, 2022
    Publication date: February 22, 2024
    Applicant: GEG TECH
    Inventor: Nicolas GRANDCHAMP
  • TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR VACCINATION
    Publication number: 20240058430
    Abstract: A method of vaccinating a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5? to 3?: an RNA Booster sequence that includes or is the following ribonucleic acid sequence mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one antigen.
    Type: Application
    Filed: August 9, 2022
    Publication date: February 22, 2024
    Applicant: GEG TECH
    Inventor: Nicolas GRANDCHAMP
  • Transient expression vectors, preparation and uses thereof
    Patent number: 10308955
    Abstract: The present invention describes a recombinant retroviral vector which cannot by itself achieve complete reverse transcription as well as its uses, in particular for transiently transferring in vitro, ex vivo or in vivo at least one ribonucleic acid sequence of interest in a cell. Such a transient transgene expression is of interest in the context of research, therapy and more generally in the field of biotechnology.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: June 4, 2019
    Assignee: NEWVECTYS
    Inventors: Chamsy Sarkis, Dorothee Altemir, Nicolas Grandchamp, Stephanie Philippe
  • TRANSIENT EXPRESSION VECTORS, PREPARATION AND USES THEREOF
    Publication number: 20140286907
    Abstract: The present invention describes a recombinant retroviral vector which cannot by itself achieve complete reverse transcription as well as its uses, in particular for transiently transferring in vitro, ex vivo or in vivo at least one ribonucleic acid sequence of interest in a cell. Such a transient transgene expression is of interest in the context of research, therapy and more generally in the field of biotechnology.
    Type: Application
    Filed: October 26, 2012
    Publication date: September 25, 2014
    Inventors: Chamsy Sarkis, Dorothee Altemir, Nicolas Grandchamp, Stephanie Philippe